Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0NLWKV)
| ADC Name |
SGN-CD19B
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SGN-CD19B
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
HBU12ec
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
talirine
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility requires measurable disease after ≥2 prior systemic therapies with ECOG 0-1 and adequate organ function, excluding patients with prior CD19-targeted therapy (unless CD19+ confirmed), active infections, allogeneic transplants, or recent anticancer treatments within 4 weeks (2 weeks if progressive disease).
|
||||
| Administration Dosage |
Given intravenously Day 1 of 28-day or 42-day cycles
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02702141 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma | ||||
| Primary Endpoint |
The primary endpoints evaluate safety profiles including adverse event incidence and laboratory abnormalities monitored through 1 month post-treatment in relapsed/refractory patients.
|
||||
| Other Endpoint |
Secondary objectives assess pharmacokinetics (SGN-CD19B blood concentrations for 3 weeks), immunogenicity (antitherapeutic antibodies), and efficacy measures (objective response rate, progression-free survival up to 3 years) in this heavily pretreated population.
|
||||